Fundraising FoxUCB Ventures
Venture capitalBrussels · Seed–Series A · 5 people tracked
Find your way into UCB Ventures
720 people in our graph can introduce you to the UCB Ventures team.
Sign up to see every warm intro you have to UCB Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the UCB Ventures team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
UCB Ventures is a €150 million corporate venture fund established in 2017 that invests in early-stage therapeutics and technology platforms in neurology, neurodegenerative diseases, immunology, and musculoskeletal/bone health. The fund focuses on innovative companies adjacent to or outside UCB's core therapeutic areas.
Team · 5 people
from public directories
What they invest in
from 9 of 9 portfolio companiesBiotech ×9Deep Tech ×8Healthtech ×5Medical Devices ×4Digital Health ×3AI & Machine Learning ×1
HQs:United States×4Belgium×1Spain×1United Kingdom×1
Investments · 9 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 12022 · 22020 · 15 dated
ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations.
BiotechDeep TechDigital HealthHealthtechMedical DevicesGhent, BE
Xavier Saelens(Scientific Founder)Nico Callewaert(Scientific Founder)inMike Garrett(Chief Executive Officer)
Co-investorsV-Bio VenturesSambrinvestVIBFund+VIVES Partners
Iris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles.
BiotechDeep TechHealthtech
Megan Matthews(Co-founder & President)Megan Blewett(Founder)
Co-investorsVenrockPsyMed Ventures
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)inDeepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Dylan Morris(Director)in
Board seatAlicia Irurzun-Lafitte· per SEC Form D · $36M raise · filed Nov 2022
Co-investorsBold Capital PartnersCRV (Charles River Ventures)Dolby Family VenturesFREEFLOWGlobal BrainOno Venture Investment, Inc.+3 more
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond Ventures+1 more
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupViking GlobalYsios CapitalAlexandria+8 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence Capital+8 more
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsAsabys PartnersNovartis Venture FundRoche Venture FundSanofi VenturesYsios CapitalCriteria Bio Ventures+3 more
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsCambridge Angels groupOxford Investment Opportunity Network (OION)4BIO CapitalOrigin Capital
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical Devices
Co-investorsARCH Venture PartnersATEM Capital FundPandect Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companiesSonoThera · finsmes.com · Jun 10, 2026
Frequently asked questions
- How many investments has UCB Ventures made?
- UCB Ventures has 9 tracked investments, including 1 dated in the last 24 months.
- What stage does UCB Ventures invest at?
- UCB Ventures invests at the Seed, Series A stages.
- What sectors does UCB Ventures focus on?
- UCB Ventures focuses on Biotech, Medical Devices.
- Where is UCB Ventures located?
- UCB Ventures is headquartered in Brussels, BE.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.